This article is more than 5 years old. Information may no longer be current.
NeoVista's epiretinal beta radiation therapy acquires category III CPT code
Click Here to Manage Email Alerts
FREMONT, Calif. — The American Medical Association Current Procedural Terminology Editorial Panel has released a new category III CPT code for NeoVista's radiation therapy for treating wet age-related macular degeneration. The code will become effective on July 1, according to a press release from NeoVista.
The code — 0190T — will be used in conjunction with the code for performing a basic posterior vitrectomy (67036) and will allow physicians to identify the novel radiation therapy on insurance claims, according to the release.
"Obtaining a category III CPT code is a vital step towards our end-goal of seeing our therapy through to market launch, where it will be of help to millions of people suffering from wet AMD," said John Hendrick, president and CEO of NeoVista, in the release.
During the code development and acquisition process, representatives from the American Academy of Ophthalmology and the American Society of Therapeutic and Radiation Oncology expressed interest and support for the new treatment, which is currently in an ongoing pivotal trial, the release said.